Showing results (61-70 of 130) with videos related to
Sort By:
Pageof 13
Expert Review of Molecular Diagnostics|October 23, 2010
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Karin Mengele, Rudolf Napieralski, Viktor Magdolen, et al.Breast Cancer Research and Treatment|July 17, 2010
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivoSumito Sato, Charlotte Kopitz, Bettina Grismayer, et al.Histopathology|September 16, 2010
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinomaMatthias Kotzsch, Katharina Bernt, Katrin Friedrich, et al.Biological Chemistry|August 18, 2016
In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1BJanet C Reid, Nigel C Bennett, Carson R Stephens, et al.American Journal of Translational Research|April 12, 2021
Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancerWeiwei Gong, Caixia Zhu, Yueyang Liu, et al.Radiology and Oncology|December 3, 2013
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignanciesManfred Schmitt, Viktor Magdolen, Feng Yang, et al.Biomaterials|July 6, 2013
A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spreadDaniela Loessner, Simone C Rizzi, Kathryn S Stok, et al.European Journal of Immunology|July 21, 2018
Kallikrein-related peptidases are activators of the CC chemokine CCL14Mario Grünberg, Dagmar Quandt, Holger Cynis, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2007
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancerSebastian Knör, Sumito Sato, Timo Huber, et al.Journal of Medicinal Chemistry|November 1, 2002
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimeticsNiko Schmiedeberg, Manfred Schmitt, Christian Rölz, et al.Pageof 13